SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVR: BULLS AND BEARS!
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: OLD JAKE JUSTUS who started this subject7/26/2000 2:57:20 PM
From: KAKALAK  Read Replies (1) of 8902
 
NEWS>>>>>>>>>>>

AIDS Treatment Activists Call for Fast Track Development of Reticulose

NEW YORK, July 26 /PRNewswire/ -- With the close of the 13th International
AIDS Conference, a coalition of leading AIDS Treatment activists are demanding
better access to Reticulose, a lipoprotein-nucleic acid complex manufactured
by Advanced Viral Research that has shown promise in the treatment of many of
the symptoms of HIV disease. Reticulose is presently available through a
compassionate use program approved by the FDA, but many activists are claiming
this is not enough.
"Many people presently receiving Reticulose through the compassionate
access program are doing better but there are hundreds of thousands of people
living with AIDS who need access to this promising therapy but can't receive
it," said David Miller, Director of Brooklyn Medical Arts AIDS CARE Center and
a member of ACT UP Brooklyn. "We are urging Advanced Viral Research to peruse
federal clinical research and to apply for fast track designation at the FDA
to accelerate access for the thousands that are intolerant to the side effects
of antiviral therapy."
Jeannie Gibbs, a veteran AIDS treatment activist now working with the
International HIV IBT Working Group is petitioning FDA officials and
legislators to move aggressively to ensure access to Reticulose. "I'm
confident we're going to secure the necessary support to encourage the
development of Reticulose in the next few weeks."
Advanced Viral Research is presently pursuing mature discussions with
leading clinical research organizations including Anderson Clinical Research
Institute who will be retained to execute trials in HIV patients during the
next two to three months.
Sources close to the company revealed that dramatic in vitro results of a
study analyzing the potential of Reticulose for the treatment of HIV will be
submitted for presentation during the 38th annual meeting of the Infectious
Disease Society of America taking place September 7-10, 2000 in New Orleans,
LA.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News